Non-vitamin K antagonist oral anticoagulants (NOACs) were marketed in 2011 as alternatives to Vitamin K Antagonists (VKA) for treatment of thromboembolic risk in atrial fibrillation (AF) patients. Pivotal studies demonstrated the non-inferior effectiveness and the superior safety of NOACs compared to VKAs. International guidelines currently recommend NOACs over VKAs for thromboprophylaxis of AF [1], leading to a progressive uptake of NOACs [2]. One of the crucial aspect in the management of NOACs, is the appropriate choice of the drug dose [1].
